Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Domoprednate is a synthetic glucocorticoid corticosteroid developed in the late 1970s and 1980s for topical use. It acts as an anti-inflammatory and anti-allergic agent by modulating gene expression through the glucocorticoid receptor, leading to reduced production of inflammatory mediators. Domoprednate is considered a medium-active corticosteroid and has been used topically to treat skin disorders such as eczema, psoriasis, and atopic dermatitis. Clinical studies indicate its efficacy is comparable to hydrocortisone butyrate for these indications[1][2][5]. It is nonhalogenated and generally well tolerated.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on domoprednate.